Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATION: Durvalumab in Advanced Oesophageal Cancer
NCT03653052Phase 2Active, not recruiting
- Start
- Oct 2018
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in esophageal cancer. Primary endpoint: Clinical response to therapy (durvalumab) at 26 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03653052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653052.